These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 21308879)

  • 1. Influenza virus H5N1 hemagglutinin (HA) T-cell epitope conjugates: design, synthesis and immunogenicity.
    Skarlas T; Zevgiti S; Droebner K; Panou-Pomonis E; Planz O; Sakarellos-Daitsiotis M
    J Pept Sci; 2011 Mar; 17(3):226-32. PubMed ID: 21308879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational analysis of proteome of H5N1 avian influenza virus to define T cell epitopes with vaccine potential.
    Parida R; Shaila MS; Mukherjee S; Chandra NR; Nayak R
    Vaccine; 2007 Oct; 25(43):7530-9. PubMed ID: 17900763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.
    Matsui M; Kohyama S; Suda T; Yokoyama S; Mori M; Kobayashi A; Taneichi M; Uchida T
    Biochem Biophys Res Commun; 2010 Jan; 391(3):1494-9. PubMed ID: 20060099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of linear and comb-like peptide constructs containing up to four copies of a T cell epitope and their capacity to stimulate T cells.
    Mack J; Falk K; Rötzschke O; Walk T; Strominger JL; Jung G
    J Pept Sci; 2001 Jun; 7(6):338-45. PubMed ID: 11461048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates.
    Krikorian D; Panou-Pomonis E; Voitharou C; Sakarellos C; Sakarellos-Daitsiotis M
    Bioconjug Chem; 2005; 16(4):812-9. PubMed ID: 16029022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of epitopes in hemagglutinin and neuraminidase proteins of influenza A virus H5N1 strain: a clue for diagnostic and vaccine development.
    Somvanshi P; Singh V; Seth PK
    OMICS; 2008 Mar; 12(1):61-9. PubMed ID: 18266559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytolytic T lymphocyte and antibody responses to synthetic peptides of influenza virus hemagglutinin.
    Wabuke-Bunoti MA; Taku A; Fan DP; Kent S; Webster RG
    J Immunol; 1984 Oct; 133(4):2194-201. PubMed ID: 6206156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza A virus-specific H-2d restricted cross-reactive cytotoxic T lymphocyte epitope(s) detected in the hemagglutinin HA2 subunit of A/Udorn/72.
    Saikh KU; Martin JD; Nishikawa AH; Dillon SB
    Virology; 1995 Dec; 214(2):445-52. PubMed ID: 8553546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.
    Kreijtz JH; Bodewes R; van den Brand JM; de Mutsert G; Baas C; van Amerongen G; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    Vaccine; 2009 Aug; 27(36):4983-9. PubMed ID: 19538996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening.
    Wang M; Lamberth K; Harndahl M; Røder G; Stryhn A; Larsen MV; Nielsen M; Lundegaard C; Tang ST; Dziegiel MH; Rosenkvist J; Pedersen AE; Buus S; Claesson MH; Lund O
    Vaccine; 2007 Apr; 25(15):2823-31. PubMed ID: 17254671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
    Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic and immunogenic properties of synthetic peptide-based T-cell determinant polymers.
    Jackson DC; Fitzmaurice C; Sheppard RC; McMurray J; Brown LE
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):171-6. PubMed ID: 9346849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recognition of a viral antigenic moiety by class I MHC-restricted cytolytic T lymphocytes is limited by the availability of the endogenously processed antigen.
    Milligan GN; Morrison LA; Gorka J; Braciale VL; Braciale TJ
    J Immunol; 1990 Nov; 145(10):3188-93. PubMed ID: 1700000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
    Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
    Morgan DJ; Kreuwel HT; Fleck S; Levitsky HI; Pardoll DM; Sherman LA
    J Immunol; 1998 Jan; 160(2):643-51. PubMed ID: 9551898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.